SAN DIEGO

,

July 28, 2021

/PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on

Wednesday, August 11, 2021

at

4:30 p.m. ET

(

1:30 p.m. PT

).

The webcast (live and archived) and related slide presentation can be accessed through

https://evofem.investorroom.com/2021Q2Results

or directly at

https://edge.media-server.com/mmc/p/h6zpy9h5

. Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required.

If participating by phone, please dial in approximately 15 minutes prior to the start of the call using (866) 503-5561 (U.S. toll-free) or (253) 336-2965, and referring to conference ID 9190716.

A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 9190716.

About Evofem Biosciences


Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product,

Phexxi®

(lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital

Chlamydia trachomatis

and

Neisseria gonorrhoeae

infection in women in the ongoing Phase 3 clinical trial,

‘EVOGUARD

.’ For more information, please visit

evofem.com

.

Phexxi

^®

is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact



Amy Raskopf


Evofem Biosciences, Inc.



[email protected]



Mobile: (917) 673-5775

View original content to download multimedia:

https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2021-results-and-provide-corporate-update-on-wednesday-august-11-2021-301342050.html

SOURCE Evofem Biosciences, Inc.